Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Monday, November 30, 2020

Paediatric Molecular Radiotherapy: Challenges and Opportunities.

xlomafota13 shared this article with you from Inoreader

pubmed-meta-image.png

Related Articles

Paediatric Molecular Radiotherapy: Challenges and Opportunities.

Clin Oncol (R Coll Radiol). 2020 Nov 24;:

Authors: Aldridge MD, Peet C, Wan S, Shankar A, Gains JE, Bomanji JB, Gaze MN

Abstract
The common contemporary indications for paediatric molecular radiotherapy (pMRT) are differentiated thyroid cancer and neuroblastoma. It may also have value in neuroendocrine cancers, and it is being investigated in clinical trials for other diseases. pMRT is the prototypical biomarker-driven, precision therapy, with a unique mode of delivery and mechanism of action. It is safe and well tolerated, compared with other treatments. However, its full potential has not yet been achieved, and its wider use faces a number of challenges and obstacles. Paradoxically, the success of radioactive iodine as a curative treatment for metastatic thyroid cancer has led to a 'one size fits all' approach and limited academic enquiry into optimisation of the conventional treatment regimen, until very recently. Second, the specialised requirements for the delivery of pMRT are available in only a very limited number of centres. This limited capacity and geographical coverage results in reduced acc essibility. With few enthusiastic advocates for this treatment modality, investment in research to improve treatments and broaden indications from both industry and national and charitable research funders has historically been suboptimal. Nonetheless, there is now an increasing interest in the opportunities offered by pMRT. Increased research funding has been allocated, and technical developments that will permit innovative approaches in pMRT are available for exploration. A new portfolio of clinical trials is being assembled. These studies should help to move at least some paediatric treatments from simply palliative use into potentially curative protocols. Therapeutic strategies require modification and optimisation to achieve this. The delivery should be personalised and tailored appropriately, with a comprehensive evaluation of tumour and organ-at-risk dosimetry, in alignment with the external beam model of radiotherapy. This article gives an overview of the current status of p MRT, indicating the barriers to progress and identifying ways in which these may be overcome.

PMID: 33246658 [PubMed - as supplied by publisher]

View on the web

No comments:

Post a Comment